T 0159/11 (Competitive hybridization/QUEST DIAGNOSTICS) 05-04-2017

Reasons for the Decision

Admission of the new sets of claims into the proceedings

1. Pursuant to Article 12(4) of the Rules of Procedure of the Boards of Appeal (RPBA) in conjunction with Article 114(2) EPC, it is a matter of discretion of the board whether or not requests and evidence filed for the first time in appeal proceedings, but which could have been presented in the previous proceedings, are admitted and considered.

2. The sets of claims according to the main request and auxiliary request 2 filed by the appellant together with the statement of grounds of appeal are, undisputedly, fresh sets of claims as they were not on file in opposition proceedings. Moreover, contrary to the respondent's view, also the claims according to auxiliary request 1 have to be considered as fresh claims. Even though in opposition proceedings the appellant proposed a draft claim which included the feature introduced into claim 1 of the present auxiliary request 1, the wording of that claim differed slightly from the wording of claim 1 as now on file. Thus, it cannot be excluded that the difference in wording reflects a difference in subject-matter claimed. In any case, the circumstances of the present case do not seem to support the respondent's assumption that, by not pursuing the draft claim further, the patent proprietor (the present appellant) deliberately attempted to prevent a decision of the opposition division on that particular claim.

3. The amendments introduced into the claims filed together with the statement of grounds of appeal are clearly intended to address the opposition division's adverse findings on novelty (Article 54 EPC) with respect to the main request then on file. The question whether or not these sets of claims could - and should - have been filed in opposition proceedings has to be answered having regard to the particular circumstances of the present case. It should be noted that the circumstances underlying previous decisions of the Boards of Appeal on the admission of fresh sets of claims into the appeal proceedings on which the respondent relied (see section XII above), including those by the present board differ from the circumstances in the present case. In fact, identical circumstances are unlikely.

4. In the present case, in a communication issued in preparation for oral proceedings the opposition division expressed the provisional opinion that the subject-matter of both the claims on file and the proposed claim lacked novelty over two documents, one of which had been filed by the opponent after expiry of the period for opposition. In reply to the opposition division's communication, the patent proprietor submitted seven auxiliary requests in order to overcome the novelty objections.

5. After the discussion of the main request at the oral proceedings, the opposition division expressed the view that only one of the documents relied upon by the opponent was prejudicial to the novelty. As a reaction, the patent proprietor withdrew several auxiliary requests, renumbered a previous request as 1**(st) auxiliary request and filed a fresh set of claims as 2**(nd) auxiliary request. The amendments introduced into the claims according to the 1**(st) and 2**(nd) auxiliary request were however found to contravene Article 123(2) EPC and the claims to lack clarity and conciseness within the meaning of Article 84 EPC (see sections 4.3 and 5.2 of the minutes of the oral proceedings before the opposition division).

6. The sets of claims submitted together with the statement of grounds of appeal are an attempt to remedy deficiencies of the claims underlying the decision under appeal which became apparent at a late stage of the oral proceedings before the opposition division. Since there is no clear proof of any abuse of procedure, the board, exercising its discretion, decided to admit the three sets of claims into the proceedings.

Main request - Article 123(2) EPC

7. In the decision under appeal, the opposition division found that the objections under Article 123(2) EPC raised by the opponent with respect to claim 1 of the main request then on file were not justified (see points 14.2.3 and 14.3.3 of the decision). This finding has not been contested in appeal proceedings.

8. Thus, the sole question to be decided is whether the amendment introduced into present claim 1 complies with Article 123(2) EPC. Present claim 1 differs from the corresponding claim of the main request underlying the decision under appeal in that it includes the further feature "... wherein the first oligonucleotide probe is in the range of 15-60 nucleotides in length ...". As basis for this feature, the appellant relied on the statements on page 4, lines 7 to 9, and on probe C1 in Table III on page 8 of the application as filed. The passage on page 4, lines 7 to 9 reads:

"Preferably, theoligonucleotide [sic] probe is in the range of 15-60 nucleotides in length"

9. Contrary to the appellant's view, this passage does not disclose that the length of the first probe is in the range of 15-60 nucleotides, as specified in claim 1. As a matter of fact, the passage in question is ambiguous because it mentions an oligonucleotide probe (in singular), but leaves open to which of the two probes used in the method for monitoring nucleic acid amplification, the first probe having a fluorophore and the second having a quencher, the disclosed length range applies.

10. Example 1 does not shed light on the question which of the two probes is meant in the passage quoted above. While it is true that the first probe shown in Table III of Example 1 (probe C1) has a length of 20 nucleotides and is, thus, within the range disclosed in the passage on page 4, the same is true for the second probe (probe C2) which has a length of 17 nucleotides. Hence, from the passage on which the appellant relies read in connection with Example 1 a person skilled in the art cannot derive, clearly and unambiguously, a method as claimed in claim 1 in which only the first oligonucleotide probe is in the range of 15-60 nucleotides in length, whereas the length of the second probe is not subject to any limitation other than that it is at least 2 nucleotides ("base pairs") shorter than the first probe.

11. The appellant relied further on the passages on page 3, lines 34 to 38 and page 4, lines 9 to 16 of the application as filed. On page 3, it is stated that the oligonucleotide probes of the invention can be synthesized by a number of approaches, conveniently on an automated DNA synthesizer using standard chemistries. There is no link apparent between this general disclosure, which applies to all probes, and the disclosure of a particular embodiment ("Preferably") concerning the length of a single probe ("theoligonucleotide probe"). More importantly, the passage on page 3 does not concern specifically the first probe, but any probe used in the method of the invention.

12. Nor does the passage on page 4 indicated by the appellant, which reads:

"The precise sequence and length of an oligonucleotide probe of the invention depends in part on the nature of the target polynucleotide to which it binds. The binding location and length may be varied to achieve appropriate annealing and melting properties for a particular embodiment. Preferably, the 3' terminal nucleotide of the oligonucleotide probe is blocked or rendered incapable of extension by a nucleic acid polymerase. Such blocking is conveniently carried out by the attachment of a reporter or quencher molecule to the terminal 3' carbon of the oligonucleotide probe by a linking moiety."

(see page 4, lines 9 to 16)

Neither the statements in the first two sentences of this passage, which deal generally with the sequence, binding location and length of an oligonucleotide probe of the invention, nor the last two sentences, which relate to a specific embodiment, provide any information which would help the person skilled in the art to resolve the ambiguity in the previous sentence.

13. It follows from the above that the method of amended claim 1 cannot be derived directly and unambiguously from the application as filed. Since the amendment introduced into claim 1 contravenes Article 123(2) EPC, the patent cannot be maintained on the basis of the claims according to the main request.

Auxiliary request 1 - Article 123(2) EPC

14. As basis for the amendment introduced into claim 1 (see section VI above), the appellant relied on the same passage of the application as filed as for the amendment in claim 1 of the main request (see paragraph 8 above). It is stated in the passage in question that the oligonucleotide probe (in singular) is in the range of 15-60 nucleotides in length. Hence, this passage explicitly discloses the length of only one (unspecified) oligonucleotide probe, rather than of both the first and second probe, as in amended claim 1.

15. Neither the context in which the passage is found in the application, nor Example 1 can be acknowledged as an implicit disclosure of the feature introduced into claim 1. As stated above in connection with the main request, the passage starting on page 3, line 34 discloses a number of approaches for the synthesis of the oligonucleotide probes of the invention. The following passage, however, explicitly relates to a preferred embodiment characterized by the length of the (unspecified) nucleotide probe. There is no inconsistency between both disclosures which may induce the skilled person to read the wording "the nucleotide probe is ..." as meaning "both nucleotide probes are ...". The fact that both the first probe (C1) and the second probe (C2) in Example 1 have a length within the range of 15-60 nucleotides (20 and 17 nucleotides, respectively) is consistent with the requirement that the second (shorter) oligonucleotide probe varies in length from the first probe by at least 2 base pairs (see page 2, lines 5 and 6 of the application) and is not in contradiction with the statement on page 4. Thus, in view of Example 1 a person skilled in the art would not consider that the actual length of the oligonucleotide probes in the example necessarily implied that both probes need to be 15-60 nucleotides in length.

16. Summarizing the above, it is concluded that there is neither explicit nor implicit disclosure in the application as filed of a method as defined in claim 1. Consequently, the subject-matter of this claim extends beyond the content of the application as filed and thus offends against Article 123(2) EPC.

Auxiliary request 2 - Article 123(2) EPC

17. Amended claim 1 according to auxiliary request 2 differs from the corresponding claim of the previous request in that the range has been limited to 15-30 nucleotides. The appellant relies on the passage on page 4, lines 7 to 9 of the application as filed as basis for this amendment. This passage reads:

"Preferably, theoligonucleotide [sic] probe is in the range of 15-60 nucleotides in length. More preferably, the oligonucleotide probe is in the range of 18-30 nucleotides in length."

18. The length range specified in claim 1 results from a combination of the lower and upper limit of the two ranges disclosed in this passage. However, in the context of Article 123(2) EPC the decisive issue is whether a person skilled in the art can derive from the passage in question the feature that both the first and second oligonucleotide probe are in the specified length range. For the same reasons as given in connection with the first auxiliary request (see paragraph 15 above), it is considered that this passage, read either alone or in combination with further technical information in the application, in particular Example 1, does not disclose, clearly and unambiguously, a method as claimed. Hence, the amendment introduced into claim 1 contravenes Article 123(2) EPC.

Conclusion

19. None of the sets of claims on file complies with Article 123(2) EPC. Thus, the appellant's request to set aside the decision under appeal and maintain the patent on the basis of any of these sets of claims cannot be granted.